{"id":3247,"date":"2020-05-01T16:49:00","date_gmt":"2020-05-01T14:49:00","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=3247"},"modified":"2021-02-05T16:52:06","modified_gmt":"2021-02-05T15:52:06","slug":"rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/","title":{"rendered":"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Abstract<\/h4>\n\n\n\n<p><strong>Background:<\/strong> Safety data about rilpivirine use during pregnancy remain scarce, and rilpivirine plasma concentrations are reduced during second\/third trimesters, with a potential risk of viral breakthroughs. Thus, French guidelines recommend switching to rilpivirine-free combinations (RFCs) during pregnancy.<\/p>\n\n\n\n<p><strong>Objectives:<\/strong> To describe the characteristics of women initiating pregnancy while on rilpivirine and to compare the outcomes for virologically suppressed subjects continuing rilpivirine until delivery versus switching to an RFC.<\/p>\n\n\n\n<p><strong>Methods:<\/strong> In the ANRS-EPF French Perinatal cohort, we included women on rilpivirine at conception in 2010-18. Pregnancy outcomes were compared between patients continuing versus interrupting rilpivirine. In women with documented viral suppression (&lt;50 copies\/mL) before 14 weeks of gestation (WG) while on rilpivirine, we compared the probability of viral rebound (\u226550 copies\/mL) during pregnancy between subjects continuing rilpivirine versus those switching to RFC.<\/p>\n\n\n\n<p><strong>Results:<\/strong> Among 247 women included, 88.7% had viral suppression at the beginning of pregnancy. Overall, 184 women (74.5%) switched to an RFC (mostly PI\/ritonavir-based regimens) at a median gestational age of 8.0 WG. Plasma HIV-1 RNA nearest delivery was &lt;50 copies\/mL in 95.6% of women. Among 69 women with documented viral suppression before 14 WG, the risk of viral rebound was higher when switching to RFCs than when continuing rilpivirine (20.0% versus 0.0%, P = 0.046). Delivery outcomes were similar between groups (overall birth defects, 3.8\/100 live births; pregnancy losses, 2.0%; preterm deliveries, 10.6%). No HIV transmission occurred.<\/p>\n\n\n\n<p><strong>Conclusions:<\/strong> In virologically suppressed women initiating pregnancy, continuing rilpivirine was associated with better virological outcome than changing regimen. We did not observe a higher risk of adverse pregnancy outcomes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093\/jac\/dkaa017. PMID: 32157283.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-3247","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093\/jac\/dkaa017. PMID: 32157283.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2021-02-05T15:52:06+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/\",\"name\":\"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\"},\"datePublished\":\"2020-05-01T14:49:00+00:00\",\"dateModified\":\"2021-02-05T15:52:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.instagram.com\/fhupremimpact\/\",\"https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/","og_locale":"en_US","og_type":"article","og_title":"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT","og_description":"J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093\/jac\/dkaa017. PMID: 32157283.","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2021-02-05T15:52:06+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/","name":"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch? - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2020-05-01T14:49:00+00:00","dateModified":"2021-02-05T15:52:06+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/rilpivirine-in-hiv-1-positive-women-initiating-pregnancy-to-switch-or-not-to-switch\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Rilpivirine in HIV-1-positive women initiating pregnancy: to switch or not to switch?"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"J Antimicrob Chemother. 2020 May 1;75(5):1324-1331. doi: 10.1093\/jac\/dkaa017. PMID: 32157283.","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/3247","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=3247"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}